Feinstein Institutes Research Identifies New Pathways in Severe Fetal Anemia, Suggesting Personalized Treatments
Researchers at the Feinstein Institutes for Medical Research have discovered that defects in different ribosomal proteins lead to Diamond-Blackfan Anemia Syndrome (DBAS) through distinct pathways. This rare blood disorder, characterized by severe anemia due to insufficient red blood cell production, has puzzled scientists due to its varied symptoms among patients. The study, published in Nature Communications, utilized advanced mouse models to explore the effects of two ribosomal proteins, RPS19 and RPL5, on blood cell development. The findings revealed that RPS19 defects cause a reduction in early blood-forming cells through apoptosis, while RPL5 issues lead to ferroptosis in more mature cells. Both pathways involve the activation of the p53 gene, which can halt cell growth or trigger cell death. The research suggests that targeting these specific pathways could lead to more effective, personalized treatments for DBAS patients. 
